SCHEMBL21986745

SCHEMBL21986745

COc1ccc2nn(C3CCCCO3)nc2c1CN

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ TSHR P16473 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ CD274 Q9NZQ7 1/20 0.31
▸ FGFR1 P11362 1/20 0.31
▸ FGFR2 P21802 1/20 0.31
▸ FGFR4 P22455 1/20 0.31
▸ FGFR3 P22607 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.30
▸ GLA P06280 2/20 0.30
▸ HPGD P15428 2/20 0.30
▸ GAA P10253 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ HIF1A Q16665 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21986849 0.89 FGFR1 (0.34) ATRALDH1A1TSHRNPSR1FGFR1
SCHEMBL21986862 0.85 CYP4F2 (0.33) ATRGAACYP2C19
SCHEMBL21986791 0.78 ALDH1A1 (0.36) ATRALDH1A1NPSR1KDM4EGLA
SCHEMBL21986816 0.76 ATR (0.36) ATRALDH1A1TSHRNPSR1CD274
SCHEMBL21986838 0.76 ALDH1A1 (0.35) ATRALDH1A1TSHRNPSR1CD274
SCHEMBL21986817 0.75 CYP4F2 (0.35) ATRALDH1A1FGFR1FGFR2FGFR4
SCHEMBL21986801 0.75 CYP4F2 (0.33) ATRTSHRCYP2C19
SCHEMBL21986700 0.70 ATR (0.36) ATRALDH1A1TSHRNPSR1CD274
SCHEMBL21986808 0.70 SLC6A3 (0.39) ATRALDH1A1NPSR1CD274HPGD
SCHEMBL21986706 0.67 ALDH1A1 (0.35) ATRALDH1A1TSHRNPSR1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660003-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-01-24 — — EP disclosed
US-11713311-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-01 — — US disclosed
US-20220388995-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-08 — — US disclosed
US-11230541-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-25 — — US disclosed
US-20200231579-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed
EP-3660003-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-06-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230541-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B ATR 3544/4885ALDH1A1 3354/4885TSHR 2673/4885
US-20200231579-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B ATR 3544/4885ALDH1A1 3354/4885TSHR 2673/4885
US-11713311-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B ATR 3544/4885ALDH1A1 3354/4885TSHR 2673/4885
US-20220388995-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B ATR 3544/4885ALDH1A1 3354/4885TSHR 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback